

08 Nov 2021 | News

Quick Listen: Scrip's Five Must-Know Things

by Ian Haydock

In this week's podcast edition of Five Must-Know Things: Pfizer's mixed Q3; delayed US approval for Janssen/Legend's CAR-T; promising new data in RSV; Dr Reddy's lays out more COVID product plans; and experts dissect decentralized trials.

Join us for an audio catch-up on the major events in the biopharma industry over the past business week, as reported by Scrip's global team, in this podcast version of Five Must-Know Things.

This episode covers insights for the business week ended 29 October 2021, including: [Pfizer Inc.](#)'s mixed Q3; delayed US approval for [Janssen Pharmaceutical Cos./Legend Biotech Corp.](#)'s CAR-T; promising new data in RSV; [Dr. Reddy's Laboratories Ltd.](#)'s lays out more COVID-19 product plans; and experts dissect decentralized trials.

This and all our other podcasts are available on the Informa Pharma Intelligence channel on [Apple Podcasts](#), [Google Podcasts](#), [SoundCloud](#), [TuneIn](#) and [Spotify Podcasts](#), and via smart speakers if one of these platforms has been set up as your default podcast provider.

Stories mentioned in this episode:

(Also see "[Comirnaty Gives Booster Shot To Pfizer Q3 Sales](#)" - Scrip, 2 Nov, 2021.)

(Also see "[Approval Delayed, But Janssen/Legend's Cilta-Cel May Hit Market Just In Time](#)" - Scrip, 2 Nov, 2021.)

(Also see "[Pfizer's RSV Vaccine Springs Another Surprise, This Time In Maternal Use](#)" - Scrip, 1 Nov, 2021.)

(Also see "[Dr Reddy's Gears For Sputnik Pediatric Shot, Molnupiravir Upside](#)" - Scrip, 1 Nov, 2021.)

SCRIP

CITELINE COMMERCIAL

(Also see "[*Industry Is Moving Fast With Decentralized Trials, But Is It Too Fast?*](#)" - Scrip, 3 Nov, 2021.)

[Click here to explore this interactive content online](#) 